Epigenetic lesions in malignant melanoma

Area of Science:

• Oncology
• Epigenetics
• Molecular Biology

Background:

• Malignant melanoma involves genetic and epigenetic alterations.
• Understanding metastatic melanoma biology is crucial for new treatments.
• The "methylator phenotype" characterized by gene hypermethylation is observed in melanoma.

Purpose of the Study:

• To review epigenetic approaches for treating metastatic melanoma.
• To explore the potential of DNA demethylating agents in melanoma therapy.
• To evaluate combination strategies involving epigenetic modifiers.

Main Methods:

• Review of clinical literature on 5-azacytidine and decitabine for metastatic melanoma.
• Analysis of in vitro models and clinical trials of combination therapies.
• Examination of the rationale for epigenetic therapy in melanoma treatment.

Main Results:

• DNA demethylating agents are a rational treatment approach for melanoma with a "methylator phenotype".
• Prolonged low-dose exposure to demethylating agents may enhance efficacy.
• In vitro synergism observed between DNA methylation and histone deacetylation inhibitors.

Conclusions:

• The epigenome of malignant melanoma is a promising molecular target.
• Epigenetic therapy, particularly with demethylating agents, holds potential for melanoma treatment.
• Combination therapies and immunotherapy strategies integrating epigenetic approaches warrant further investigation.